Chinese Biopharma Huahai Plummets Post FDA Shutout

Oct 10, 2018 | China, China Drug Development, FDA, FDA Recalls, Import Ban

Zhejiang Huahai Pharmaceuticals Co Ltd stock dropped in early trades on October 8 as the FDA blocked all imports of drug ingredients or medicines made by the company as reported by Epoch Times.  The makers of Valsartan (blood pressure treatment), recalled the product in the USA after impurities linked to cancer were detected.


Pin It on Pinterest